EUCTR2007-000171-41-IT进行中（未招募）不适用
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency - ND
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 176
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.7 or more year-old 2. Females of childbearing potential must be willing to use birth control (IUD; oral, transdermal or parenteral contraceptives; abstinence). 3.Diagnosis of CF based upon the following criteria: a. two clinical features consistent with CF; and b.either genotype with two identifiable mutations consistent with CF, c. or sweat chloride >60 mEq/L by quantitative pilocarpine iontophoresis. 4. Clinically stable with no evidence of acute upper or lower respiratory tract infection. 5. PI determined by fecal elastase <100 microg/g stool measured at Screening visit. 6. Able to take pancreatic enzyme supplementation in the form of capsules. 7. Able to perform the testing (e.g. stool collections) and inpatient stays required for this study, as judged by the Inestigator. 8. Willing and able to proide informed consent or assent. 9. Baseline CFA ≤80%
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient <7 years old. 2. CFA >80% at Baseline. 3. Pregnancy, breastfeeding or of childbearing potential and not willing to use birth control (IUD; oral, transdermal or parental contraceptives; abstinence) during the study. 4. History of fibrosing colonopathy. 5. History of liver transplant, lung transplant or significant surgical resection of the bowel. Significant resection of the bowel is defined as any resection of the terminal ileum, or ileo-cecal valve. Patients who have had qualitative, long-term changes in nutritional status after any other bowel resection (e.g., increased, or new, need for supplementation compared to pre-op in order to maintain the same nutritional status) should also be excluded. 6. Any acute or chronic diarrheal illness unrelated to PI (e.g. infectious gastroenteritis, sprue, lactose intolerance, inflammatory bowel disease). 7. Unable to discontinue enteral tube feedings during the study. 8. Known hypersensitivity to food additives. 9. Inability to consume the PP diets, in the judgment of the Investigator. 10. Participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the Screening Visit. 11. ALT or AST level > 5x ULN, or total bilirubin level > 1.5x ULN at the Screening Visit or at Baseline (except for patients with Gilbert Syndrome). 12. Signs and/or symptoms of liver cirrhosis or portal hypertension (e.g., splenomegaly, ascites, esophageal varices), or documented liver disease unrelated to CF?. 13. DIOS in the last six months prior to the Screening Visit. 14. Unable to discontinue the use of pancreatic enzymes. 15. Any condition that the Investigator believes would interfere with the intent of this study or would make participation not in the best interest of the patient. 16. Patient is unlikely to complete the study, as determined by the Investigator. ? Eligible patients with ALT or AST level > 3x to 5x ULN at the Screening Visit or at Baseline will be tested for viral hepatitis. Other diagnostic testing may be performed at the discretion of the Investigator.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
Efficacy and safety of Cabozantinib (XL184) in subjects who have progressed after VEGFR-targeted treatmentRadioiodine-Refractory Differentiated Thyroid Cancer which has progressed after priorVEGFR-targeted therapyMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001771-21-CZExelixis, Inc.300
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
不适用
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with Genotype-1 Chronic Hepatitis C Virus (HCV) InfectioEUCTR2009-013442-86-BEGilead Sciences Inc560
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644